The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
[P1]	 O
Docetaxel	 O
[P2]	 O
,	 O
Cisplatin	 O
,	 O
and	 O
5-Fluorouracil	 O
Vs	 O
.	 O

The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
Docetaxel	 O
,	 O
[P1]	 O
Cisplatin	 O
[P2]	 O
,	 O
and	 O
5-Fluorouracil	 O
Vs	 O
.	 O

The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
Docetaxel	 O
,	 O
Cisplatin	 O
,	 O
and	 O
[P1]	 O
5-Fluorouracil	 O
[P2]	 O
Vs	 O
.	 O

[P1]	 O
Epirubicin	 O
[P2]	 O
,	 O
Oxaliplatin	 O
,	 O
and	 O
Capecitabine	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
Docetaxel	 O
,	 O
Cisplatin	 O
,	 O
and	 O
5-Fluorouracil	 O
Vs	 O
.	 O

Epirubicin	 O
,	 O
[P1]	 O
Oxaliplatin	 O
[P2]	 O
,	 O
and	 O
Capecitabine	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
Docetaxel	 O
,	 O
Cisplatin	 O
,	 O
and	 O
5-Fluorouracil	 O
Vs	 O
.	 O

Epirubicin	 O
,	 O
Oxaliplatin	 O
,	 O
and	 O
[P1]	 O
Capecitabine	 O
[P2]	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
Docetaxel	 O
,	 O
Cisplatin	 O
,	 O
and	 O
5-Fluorouracil	 O
Vs	 O
.	 O

[P1]	 O
Epirubicin	 O
[P2]	 O
,	 O
Oxaliplatin	 O
,	 O
and	 O
Capecitabine	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
AhmadAhmadzadeh	 O

Epirubicin	 O
,	 O
[P1]	 O
Oxaliplatin	 O
[P2]	 O
,	 O
and	 O
Capecitabine	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
AhmadAhmadzadeh	 O

Epirubicin	 O
,	 O
Oxaliplatin	 O
,	 O
and	 O
[P1]	 O
Capecitabine	 O
[P2]	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
AhmadAhmadzadeh	 O

The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
[P1]	 O
Docetaxel	 O
[P2]	 O
,	 O
Cisplatin	 O
,	 O
and	 O
5-Fluorouracil	 O
Vs	 O
.	 O

The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
Docetaxel	 O
,	 O
[P1]	 O
Cisplatin	 O
[P2]	 O
,	 O
and	 O
5-Fluorouracil	 O
Vs	 O
.	 O

The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
Docetaxel	 O
,	 O
Cisplatin	 O
,	 O
and	 O
[P1]	 O
5-Fluorouracil	 O
[P2]	 O
Vs	 O
.	 O

[P1]	 O
Epirubicin	 O
[P2]	 O
,	 O
Oxaliplatin	 O
,	 O
and	 O
Capecitabine	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O

Epirubicin	 O
,	 O
[P1]	 O
Oxaliplatin	 O
[P2]	 O
,	 O
and	 O
Capecitabine	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O

Epirubicin	 O
,	 O
Oxaliplatin	 O
,	 O
and	 O
[P1]	 O
Capecitabine	 O
[P2]	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O

The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
[P1]	 O
Docetaxel	 O
[P2]	 O
,	 O
Cisplatin	 O
,	 O
and	 O
5-Fluorouracil	 O
Vs	 O
.	 O

The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
Docetaxel	 O
,	 O
[P1]	 O
Cisplatin	 O
[P2]	 O
,	 O
and	 O
5-Fluorouracil	 O
Vs	 O
.	 O

The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
Docetaxel	 O
,	 O
Cisplatin	 O
,	 O
and	 O
[P1]	 O
5-Fluorouracil	 O
[P2]	 O
Vs	 O
.	 O

[P1]	 O
Epirubicin	 O
[P2]	 O
,	 O
Oxaliplatin	 O
,	 O
and	 O
Capecitabine	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
AhmadAhmadzadeh	 O

Epirubicin	 O
,	 O
[P1]	 O
Oxaliplatin	 O
[P2]	 O
,	 O
and	 O
Capecitabine	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
AhmadAhmadzadeh	 O

Epirubicin	 O
,	 O
Oxaliplatin	 O
,	 O
and	 O
[P1]	 O
Capecitabine	 O
[P2]	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
AhmadAhmadzadeh	 O

Student	 O
Research	 O
Committee	 O
HosseinHamidi	 O
Hossein	 O
Hamidi	 O
Student	 O
Research	 O
Committee	 O
Student	 O
Research	 O
Committee	 O
The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
[P1]	 O
Docetaxel	 O
[P2]	 O
,	 O
Cisplatin	 O
,	 O
and	 O
5-Fluorouracil	 O
Vs	 O
.	 O

Student	 O
Research	 O
Committee	 O
HosseinHamidi	 O
Hossein	 O
Hamidi	 O
Student	 O
Research	 O
Committee	 O
Student	 O
Research	 O
Committee	 O
The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
Docetaxel	 O
,	 O
[P1]	 O
Cisplatin	 O
[P2]	 O
,	 O
and	 O
5-Fluorouracil	 O
Vs	 O
.	 O

Student	 O
Research	 O
Committee	 O
HosseinHamidi	 O
Hossein	 O
Hamidi	 O
Student	 O
Research	 O
Committee	 O
Student	 O
Research	 O
Committee	 O
The	 O
Efficacy	 O
and	 O
Safety	 O
of	 O
Modified	 O
Docetaxel	 O
,	 O
Cisplatin	 O
,	 O
and	 O
[P1]	 O
5-Fluorouracil	 O
[P2]	 O
Vs	 O
.	 O

[P1]	 O
Epirubicin	 O
[P2]	 O
,	 O
Oxaliplatin	 O
,	 O
and	 O
Capecitabine	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
10.31557	 O
/	 O
APJCP.2020.21.3.727	 O

Epirubicin	 O
,	 O
[P1]	 O
Oxaliplatin	 O
[P2]	 O
,	 O
and	 O
Capecitabine	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
10.31557	 O
/	 O
APJCP.2020.21.3.727	 O

Epirubicin	 O
,	 O
Oxaliplatin	 O
,	 O
and	 O
[P1]	 O
Capecitabine	 O
[P2]	 O
Regimen	 O
in	 O
the	 O
Advanced	 O
Gastric	 O
Cancer	 O
:	 O
A	 O
Randomized	 O
Controlled	 O
Clinical	 O
Trial	 O
10.31557	 O
/	 O
APJCP.2020.21.3.727	 O

Eligible	 O
subjects	 O
were	 O
randomly	 O
divided	 O
into	 O
two	 O
groups	 O
by	 O
block	 O
randomization	 O
method	 O
,	 O
and	 O
finally	 O
,	 O
21	 O
patients	 O
in	 O
the	 O
m	 O
-	 O
[P1]	 O
DCF	 O
arm	 O
[P2]	 O
and	 O
19	 O
patients	 O
in	 O
the	 O
EOX	 O
arm	 O
were	 O
enrolled	 O
.	 O

Eligible	 O
subjects	 O
were	 O
randomly	 O
divided	 O
into	 O
two	 O
groups	 O
by	 O
block	 O
randomization	 O
method	 O
,	 O
and	 O
finally	 O
,	 O
21	 O
patients	 O
in	 O
the	 O
m	 O
-	 O
DCF	 O
arm	 O
and	 O
19	 O
patients	 O
in	 O
the	 O
[P1]	 O
EOX	 O
arm	 O
[P2]	 O
were	 O
enrolled	 O
.	 O

The	 O
first	 O
group	 O
received	 O
the	 O
[P1]	 O
m	 O
-	 O
DCF	 O
[P2]	 O
regimen	 O
as	 O
follows	 O
:	 O
docetaxel	 O
(	 O
40	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Sanofi	 O
,	 O
France	 O
)	 O
,	 O
diluted	 B-DOSAGE
in	 I-DOSAGE
500	 I-DOSAGE
mL	 I-DOSAGE
of	 I-DOSAGE
normal	 I-DOSAGE
saline	 I-DOSAGE
and	 O
infused	 O
intravenously	 O
over	 O
60	 O
minutes	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
cisplatin	 O
(	 O
40	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Mylan	 O
,	 O
France	 O
)	 O
,	 O
diluted	 B-DOSAGE
in	 I-DOSAGE
1,000	 I-DOSAGE
mL	 I-DOSAGE
of	 I-DOSAGE
normal	 I-DOSAGE
saline	 I-DOSAGE
on	 I-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
and	 I-DOSAGE
second	 I-DOSAGE
days	 I-DOSAGE
and	 O
infused	 O
intravenously	 O
over	 O
60	 O
minutes	 O
;	 O
and	 O
5-fluorouracil	 O
(	 O
400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Ebewe	 O
,	 O
Australia	 O
)	 O
,	 O
administered	 O
via	 O
central	 O
venous	 O
catheters	 O
from	 O
the	 O
first	 B-DOSAGE
to	 I-DOSAGE
fourth	 I-DOSAGE
day	 I-DOSAGE
.	 O

The	 O
first	 O
group	 O
received	 O
the	 O
m	 O
-	 O
DCF	 O
regimen	 O
as	 O
follows	 O
:	 O
[P1]	 O
docetaxel	 O
[P2]	 O
(	 O
40	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Sanofi	 O
,	 O
France	 O
)	 O
,	 O
diluted	 B-DOSAGE
in	 I-DOSAGE
500	 I-DOSAGE
mL	 I-DOSAGE
of	 I-DOSAGE
normal	 I-DOSAGE
saline	 I-DOSAGE
and	 O
infused	 O
intravenously	 O
over	 O
60	 O
minutes	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
cisplatin	 O
(	 O
40	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Mylan	 O
,	 O
France	 O
)	 O
,	 O
diluted	 B-DOSAGE
in	 I-DOSAGE
1,000	 I-DOSAGE
mL	 I-DOSAGE
of	 I-DOSAGE
normal	 I-DOSAGE
saline	 I-DOSAGE
on	 I-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
and	 I-DOSAGE
second	 I-DOSAGE
days	 I-DOSAGE
and	 O
infused	 O
intravenously	 O
over	 O
60	 O
minutes	 O
;	 O
and	 O
5-fluorouracil	 O
(	 O
400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Ebewe	 O
,	 O
Australia	 O
)	 O
,	 O
administered	 O
via	 O
central	 O
venous	 O
catheters	 O
from	 O
the	 O
first	 B-DOSAGE
to	 I-DOSAGE
fourth	 I-DOSAGE
day	 I-DOSAGE
.	 O

The	 O
first	 O
group	 O
received	 O
the	 O
m	 O
-	 O
DCF	 O
regimen	 O
as	 O
follows	 O
:	 O
docetaxel	 O
(	 O
40	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Sanofi	 O
,	 O
France	 O
)	 O
,	 O
diluted	 B-DOSAGE
in	 I-DOSAGE
500	 I-DOSAGE
mL	 I-DOSAGE
of	 I-DOSAGE
normal	 I-DOSAGE
saline	 I-DOSAGE
and	 O
infused	 O
intravenously	 O
over	 O
60	 O
minutes	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
[P1]	 O
cisplatin	 O
[P2]	 O
(	 O
40	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Mylan	 O
,	 O
France	 O
)	 O
,	 O
diluted	 B-DOSAGE
in	 I-DOSAGE
1,000	 I-DOSAGE
mL	 I-DOSAGE
of	 I-DOSAGE
normal	 I-DOSAGE
saline	 I-DOSAGE
on	 I-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
and	 I-DOSAGE
second	 I-DOSAGE
days	 I-DOSAGE
and	 O
infused	 O
intravenously	 O
over	 O
60	 O
minutes	 O
;	 O
and	 O
5-fluorouracil	 O
(	 O
400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Ebewe	 O
,	 O
Australia	 O
)	 O
,	 O
administered	 O
via	 O
central	 O
venous	 O
catheters	 O
from	 O
the	 O
first	 B-DOSAGE
to	 I-DOSAGE
fourth	 I-DOSAGE
day	 I-DOSAGE
.	 O

The	 O
first	 O
group	 O
received	 O
the	 O
m	 O
-	 O
DCF	 O
regimen	 O
as	 O
follows	 O
:	 O
docetaxel	 O
(	 O
40	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Sanofi	 O
,	 O
France	 O
)	 O
,	 O
diluted	 B-DOSAGE
in	 I-DOSAGE
500	 I-DOSAGE
mL	 I-DOSAGE
of	 I-DOSAGE
normal	 I-DOSAGE
saline	 I-DOSAGE
and	 O
infused	 O
intravenously	 O
over	 O
60	 O
minutes	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
cisplatin	 O
(	 O
40	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Mylan	 O
,	 O
France	 O
)	 O
,	 O
diluted	 B-DOSAGE
in	 I-DOSAGE
1,000	 I-DOSAGE
mL	 I-DOSAGE
of	 I-DOSAGE
normal	 I-DOSAGE
saline	 I-DOSAGE
on	 I-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
and	 I-DOSAGE
second	 I-DOSAGE
days	 I-DOSAGE
and	 O
infused	 O
intravenously	 O
over	 O
60	 O
minutes	 O
;	 O
and	 O
[P1]	 O
5-fluorouracil	 O
[P2]	 O
(	 O
400	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Ebewe	 O
,	 O
Australia	 O
)	 O
,	 O
administered	 O
via	 O
central	 O
venous	 O
catheters	 O
from	 O
the	 O
first	 B-DOSAGE
to	 I-DOSAGE
fourth	 I-DOSAGE
day	 I-DOSAGE
.	 O

For	 O
the	 O
second	 O
group	 O
,	 O
the	 O
[P1]	 O
EOX	 O
regimen	 O
[P2]	 O
was	 O
administered	 O
as	 O
follows	 O
:	 O
epirubicin	 O
(	 O
50	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Ebew	 O
,	 O
Austria	 O
)	 O
as	 O
intravenous	 O
bolus	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
oxaliplatin	 O
(	 O
130	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Sanofi	 O
,	 O
France	 O
)	 O
,	 O
infused	 O
over	 O
two	 O
hours	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
and	 O
capecitabine	 O
(	 O
625	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Roche	 O
,	 O
Switzerland	 O
)	 O
on	 B-DOSAGE
21	 I-DOSAGE
days	 I-DOSAGE
p.o	 O
.	 O

For	 O
the	 O
second	 O
group	 O
,	 O
the	 O
EOX	 O
regimen	 O
was	 O
administered	 O
as	 O
follows	 O
:	 O
[P1]	 O
epirubicin	 O
[P2]	 O
(	 O
50	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Ebew	 O
,	 O
Austria	 O
)	 O
as	 O
intravenous	 O
bolus	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
oxaliplatin	 O
(	 O
130	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Sanofi	 O
,	 O
France	 O
)	 O
,	 O
infused	 O
over	 O
two	 O
hours	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
and	 O
capecitabine	 O
(	 O
625	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Roche	 O
,	 O
Switzerland	 O
)	 O
on	 B-DOSAGE
21	 I-DOSAGE
days	 I-DOSAGE
p.o	 O
.	 O

For	 O
the	 O
second	 O
group	 O
,	 O
the	 O
EOX	 O
regimen	 O
was	 O
administered	 O
as	 O
follows	 O
:	 O
epirubicin	 O
(	 O
50	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Ebew	 O
,	 O
Austria	 O
)	 O
as	 O
intravenous	 O
bolus	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
[P1]	 O
oxaliplatin	 O
[P2]	 O
(	 O
130	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Sanofi	 O
,	 O
France	 O
)	 O
,	 O
infused	 O
over	 O
two	 O
hours	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
and	 O
capecitabine	 O
(	 O
625	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Roche	 O
,	 O
Switzerland	 O
)	 O
on	 B-DOSAGE
21	 I-DOSAGE
days	 I-DOSAGE
p.o	 O
.	 O

For	 O
the	 O
second	 O
group	 O
,	 O
the	 O
EOX	 O
regimen	 O
was	 O
administered	 O
as	 O
follows	 O
:	 O
epirubicin	 O
(	 O
50	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Ebew	 O
,	 O
Austria	 O
)	 O
as	 O
intravenous	 O
bolus	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
oxaliplatin	 O
(	 O
130	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Sanofi	 O
,	 O
France	 O
)	 O
,	 O
infused	 O
over	 O
two	 O
hours	 O
on	 B-DOSAGE
the	 I-DOSAGE
first	 I-DOSAGE
day	 I-DOSAGE
;	 O
and	 O
[P1]	 O
capecitabine	 O
[P2]	 O
(	 O
625	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
;	 O
Roche	 O
,	 O
Switzerland	 O
)	 O
on	 B-DOSAGE
21	 I-DOSAGE
days	 I-DOSAGE
p.o	 O
.	 O

The	 O
treatment	 O
cycle	 O
for	 O
both	 O
[P1]	 O
m	 O
-	 O
DCF	 O
[P2]	 O
and	 O
EOX	 O
treatment	 O
regimens	 O
was	 O
repeated	 O
every	 O
three	 O
weeks	 O
for	 O
a	 O
maximum	 O
of	 O
eight	 O
cycles	 O
,	 O
except	 O
for	 O
samples	 O
with	 O
disease	 O
progression	 O
,	 O
unacceptable	 O
toxicity	 O
,	 O
withdrawal	 O
from	 O
the	 O
study	 O
,	 O
or	 O
death	 O
.	 O

The	 O
treatment	 O
cycle	 O
for	 O
both	 O
m	 O
-	 O
DCF	 O
and	 O
[P1]	 O
EOX	 O
treatment	 O
[P2]	 O
regimens	 O
was	 O
repeated	 O
every	 O
three	 O
weeks	 O
for	 O
a	 O
maximum	 O
of	 O
eight	 O
cycles	 O
,	 O
except	 O
for	 O
samples	 O
with	 O
disease	 O
progression	 O
,	 O
unacceptable	 O
toxicity	 O
,	 O
withdrawal	 O
from	 O
the	 O
study	 O
,	 O
or	 O
death	 O
.	 O

Also	 O
,	 O
the	 O
two	 O
-	 O
year	 O
survival	 O
rate	 O
in	 O
the	 O
[P1]	 O
EOX	 O
group	 O
[P2]	 O
was	 O
higher	 O
than	 O
that	 O
of	 O
the	 O
m	 O
-	 O
DCF	 O
group	 O
,	 O
although	 O
the	 O
difference	 O
was	 O
not	 O
statistically	 O
significant	 O
(	 O
P	 O
>	 O
0.05	 O
)	 O
(	 O
Figure	 O
2	 O
)	 O
.	 O

In	 O
addition	 O
,	 O
the	 O
median	 B-METRIC
PFS	 I-METRIC
was	 O
7.00	 B-RESULTS
(	 I-RESULTS
95	 I-RESULTS
%	 I-RESULTS
CI	 I-RESULTS
:	 I-RESULTS
2.42	 I-RESULTS
-	 I-RESULTS
11.58	 I-RESULTS
)	 I-RESULTS
months	 I-RESULTS
in	 O
the	 O
[P1]	 O
m	 O
-	 O
DCF	 O
group	 O
[P2]	 O
and	 O
8.00	 B-RESULTS
(	 I-RESULTS
95	 I-RESULTS
%	 I-RESULTS
CI	 I-RESULTS
:	 I-RESULTS
3.97	 I-RESULTS
-	 I-RESULTS
12.03	 I-RESULTS
)	 I-RESULTS
months	 I-RESULTS
in	 O
the	 O
EOX	 O
group	 O
(	 O
Figure	 O
3	 O
)	 O
;	 O
however	 O
,	 O
there	 O
was	 O
no	 O
significant	 O
difference	 O
between	 O
the	 O
two	 O
groups	 O
(	 B-RESULTS
P	 I-RESULTS
>	 I-RESULTS
0.05	 I-RESULTS
)	 I-RESULTS
.	 O

In	 O
addition	 O
,	 O
the	 O
median	 B-METRIC
PFS	 I-METRIC
was	 O
7.00	 B-RESULTS
(	 I-RESULTS
95	 I-RESULTS
%	 I-RESULTS
CI	 I-RESULTS
:	 I-RESULTS
2.42	 I-RESULTS
-	 I-RESULTS
11.58	 I-RESULTS
)	 I-RESULTS
months	 I-RESULTS
in	 O
the	 O
m	 O
-	 O
DCF	 O
group	 O
and	 O
8.00	 B-RESULTS
(	 I-RESULTS
95	 I-RESULTS
%	 I-RESULTS
CI	 I-RESULTS
:	 I-RESULTS
3.97	 I-RESULTS
-	 I-RESULTS
12.03	 I-RESULTS
)	 I-RESULTS
months	 I-RESULTS
in	 O
the	 O
[P1]	 O
EOX	 O
group	 O
[P2]	 O
(	 O
Figure	 O
3	 O
)	 O
;	 O
however	 O
,	 O
there	 O
was	 O
no	 O
significant	 O
difference	 O
between	 O
the	 O
two	 O
groups	 O
(	 B-RESULTS
P	 I-RESULTS
>	 I-RESULTS
0.05	 I-RESULTS
)	 I-RESULTS
.	 O

Finally	 O
,	 O
80.95	 O
%	 O
of	 O
patients	 O
from	 O
the	 O
[P1]	 O
m	 O
-	 O
DCF	 O
group	 O
[P2]	 O
and	 O
73.68	 O
%	 O
of	 O
patients	 O
from	 O
the	 O
EOX	 O
group	 O
died	 O
.	 O

Finally	 O
,	 O
80.95	 O
%	 O
of	 O
patients	 O
from	 O
the	 O
m	 O
-	 O
DCF	 O
group	 O
and	 O
73.68	 O
%	 O
of	 O
patients	 O
from	 O
the	 O
[P1]	 O
EOX	 O
group	 O
[P2]	 O
died	 O
.	 O

In	 O
this	 O
study	 O
,	 O
four	 O
(	 O
21.05	 O
%	 O
)	 O
patients	 O
from	 O
the	 O
[P1]	 O
EOX	 O
group	 O
[P2]	 O
and	 O
five	 O
(	 O
23.80	 O
%	 O
)	 O
patients	 O
from	 O
the	 O
m	 O
-	 O
DCF	 O
group	 O
had	 O
a	 O
reduction	 O
in	 O
at	 O
least	 O
one	 O
dose	 O
of	 O
chemotherapy	 O
.	 O

In	 O
this	 O
study	 O
,	 O
four	 O
(	 O
21.05	 O
%	 O
)	 O
patients	 O
from	 O
the	 O
EOX	 O
group	 O
and	 O
five	 O
(	 O
23.80	 O
%	 O
)	 O
patients	 O
from	 O
the	 O
[P1]	 O
m	 O
-	 O
DCF	 O
group	 O
[P2]	 O
had	 O
a	 O
reduction	 O
in	 O
at	 O
least	 O
one	 O
dose	 O
of	 O
chemotherapy	 O
.	 O

Also	 O
,	 O
six	 O
(	 O
31.58	 O
%	 O
)	 O
patients	 O
from	 O
the	 O
[P1]	 O
EOX	 O
group	 O
[P2]	 O
and	 O
five	 O
assessed	 O
for	 O
eligibility	 O
criteria	 O
.	 O

Forty	 O
-	 O
five	 O
patients	 O
met	 O
the	 O
inclusion	 O
criteria	 O
and	 O
were	 O
divided	 O
into	 O
the	 O
[P1]	 O
m	 O
-	 O
DCF	 O
[P2]	 O
(	 O
n=21	 O
)	 O
and	 O
EOX	 O
(	 O
n=19	 O
)	 O
groups	 O
(	 O
Figure	 O
1	 O
)	 O
.	 O

Forty	 O
-	 O
five	 O
patients	 O
met	 O
the	 O
inclusion	 O
criteria	 O
and	 O
were	 O
divided	 O
into	 O
the	 O
m	 O
-	 O
DCF	 O
(	 O
n=21	 O
)	 O
and	 O
[P1]	 O
EOX	 O
[P2]	 O
(	 O
n=19	 O
)	 O
groups	 O
(	 O
Figure	 O
1	 O
)	 O
.	 O

As	 O
shown	 O
in	 O
Table	 O
2	 O
,	 O
the	 O
median	 O
survival	 O
in	 O
the	 O
[P1]	 O
m	 O
-	 O
DCF	 O
[P2]	 O
and	 O
EOX	 O
groups	 O
was	 O
14.00	 B-RESULTS
(	 I-RESULTS
95	 I-RESULTS
%	 I-RESULTS
CI	 I-RESULTS
:	 I-RESULTS
11.82	 I-RESULTS
-	 I-RESULTS
16.18	 I-RESULTS
)	 I-RESULTS
and	 I-RESULTS
(	 I-RESULTS
23.80	 I-RESULTS
%	 I-RESULTS
)	 I-RESULTS
patients	 O
from	 O
the	 O
m	 O
-	 O
DCF	 O
group	 O
experienced	 O
delays	 O
in	 O
at	 O
least	 O
one	 O
treatment	 O
cycle	 O
due	 O
to	 O
toxicity	 O
induced	 O
by	 O
chemotherapy	 O
;	 O
however	 O
,	 O
the	 O
two	 O
groups	 O
showed	 O
no	 O
significant	 O
difference	 O
(	 B-RESULTS
P	 I-RESULTS
>	 I-RESULTS
0.05	 I-RESULTS
)	 I-RESULTS
.	 O

As	 O
shown	 O
in	 O
Table	 O
2	 O
,	 O
the	 O
median	 O
survival	 O
in	 O
the	 O
m	 O
-	 O
DCF	 O
and	 O
[P1]	 O
EOX	 O
groups	 O
[P2]	 O
was	 O
14.00	 B-RESULTS
(	 I-RESULTS
95	 I-RESULTS
%	 I-RESULTS
CI	 I-RESULTS
:	 I-RESULTS
11.82	 I-RESULTS
-	 I-RESULTS
16.18	 I-RESULTS
)	 I-RESULTS
and	 I-RESULTS
(	 I-RESULTS
23.80	 I-RESULTS
%	 I-RESULTS
)	 I-RESULTS
patients	 O
from	 O
the	 O
m	 O
-	 O
DCF	 O
group	 O
experienced	 O
delays	 O
in	 O
at	 O
least	 O
one	 O
treatment	 O
cycle	 O
due	 O
to	 O
toxicity	 O
induced	 O
by	 O
chemotherapy	 O
;	 O
however	 O
,	 O
the	 O
two	 O
groups	 O
showed	 O
no	 O
significant	 O
difference	 O
(	 B-RESULTS
P	 I-RESULTS
>	 I-RESULTS
0.05	 I-RESULTS
)	 I-RESULTS
.	 O

As	 O
shown	 O
in	 O
Table	 O
2	 O
,	 O
the	 O
median	 O
survival	 O
in	 O
the	 O
m	 O
-	 O
DCF	 O
and	 O
EOX	 O
groups	 O
was	 O
14.00	 B-RESULTS
(	 I-RESULTS
95	 I-RESULTS
%	 I-RESULTS
CI	 I-RESULTS
:	 I-RESULTS
11.82	 I-RESULTS
-	 I-RESULTS
16.18	 I-RESULTS
)	 I-RESULTS
and	 I-RESULTS
(	 I-RESULTS
23.80	 I-RESULTS
%	 I-RESULTS
)	 I-RESULTS
patients	 O
from	 O
the	 O
[P1]	 O
m	 O
-	 O
DCF	 O
[P2]	 O
group	 O
experienced	 O
delays	 O
in	 O
at	 O
least	 O
one	 O
treatment	 O
cycle	 O
due	 O
to	 O
toxicity	 O
induced	 O
by	 O
chemotherapy	 O
;	 O
however	 O
,	 O
the	 O
two	 O
groups	 O
showed	 O
no	 O
significant	 O
difference	 O
(	 B-RESULTS
P	 I-RESULTS
>	 I-RESULTS
0.05	 I-RESULTS
)	 I-RESULTS
.	 O

The	 O
most	 O
common	 O
side	 O
effect	 O
(	 O
grade	 O
III	 O
and	 O
IV	 O
)	 O
in	 O
the	 O
[P1]	 O
EOX	 O
group	 O
[P2]	 O
was	 O
reduction	 O
of	 O
white	 O
blood	 O
cell	 O
(	 O
WBC	 O
)	 O
,	 O
neutrophil	 O
,	 O
and	 O
platelet	 O
counts	 O
(	 O
10.53	 O
%	 O
each	 O
)	 O
,	 O
while	 O
in	 O
the	 O
m	 O
-	 O
DCF	 O
group	 O
,	 O
the	 O
most	 O
adverse	 O
event	 O
was	 O
reduced	 O
neutrophil	 O
count	 O
(	 O
28.57	 O
%	 O
)	 O
(	 O
Table	 O
3	 O
)	 O
.	 O

Although	 O
there	 O
was	 O
no	 O
significant	 O
difference	 O
in	 O
terms	 O
of	 O
the	 O
side	 O
effects	 O
between	 O
the	 O
two	 O
groups	 O
,	 O
deep	 O
vein	 O
thrombosis	 O
(	 O
DVT	 O
)	 O
in	 O
the	 O
[P1]	 O
EOX	 O
group	 O
[P2]	 O
and	 O
neutropenic	 O
fever	 O
in	 O
the	 O
m	 O
-	 O
DCF	 O
group	 O
led	 O
to	 O
longer	 O
hospitals	 O
stays	 O
.	 O

Although	 O
there	 O
was	 O
no	 O
significant	 O
difference	 O
in	 O
terms	 O
of	 O
the	 O
side	 O
effects	 O
between	 O
the	 O
two	 O
groups	 O
,	 O
deep	 O
vein	 O
thrombosis	 O
(	 O
DVT	 O
)	 O
in	 O
the	 O
EOX	 O
group	 O
and	 O
neutropenic	 O
fever	 O
in	 O
the	 O
[P1]	 O
m	 O
-	 O
DCF	 O
[P2]	 O
group	 O
led	 O
to	 O
longer	 O
hospitals	 O
stays	 O
.	 O

Overall	 O
,	 O
10	 O
(	 O
47.61	 O
%	 O
)	 O
patients	 O
from	 O
the	 O
[P1]	 O
m	 O
-	 O
DCF	 O
[P2]	 O
group	 O
and	 O
four	 O
(	 O
21.05	 O
%	 O
)	 O
patients	 O
from	 O
the	 O
EOX	 O
group	 O
received	 O
supportive	 O
treatment	 O
during	 O
chemotherapy	 O
,	 O
although	 O
there	 O
was	 O
no	 O
significant	 O
difference	 O
between	 O
the	 O
groups	 O
(	 O
P=	 O
0.08	 O
)	 O
(	 O
Table	 O
4	 O
)	 O
.	 O

Overall	 O
,	 O
10	 O
(	 O
47.61	 O
%	 O
)	 O
patients	 O
from	 O
the	 O
m	 O
-	 O
DCF	 O
group	 O
and	 O
four	 O
(	 O
21.05	 O
%	 O
)	 O
patients	 O
from	 O
the	 O
[P1]	 O
EOX	 O
group	 O
[P2]	 O
received	 O
supportive	 O
treatment	 O
during	 O
chemotherapy	 O
,	 O
although	 O
there	 O
was	 O
no	 O
significant	 O
difference	 O
between	 O
the	 O
groups	 O
(	 O
P=	 O
0.08	 O
)	 O
(	 O
Table	 O
4	 O
)	 O
.	 O

The	 O
results	 O
of	 O
this	 O
study	 O
revealed	 O
that	 O
there	 O
is	 O
no	 O
significant	 O
difference	 O
between	 O
the	 O
[P1]	 O
m	 O
-	 O
DCF	 O
[P2]	 O
and	 O
EOX	 O
regimens	 O
regarding	 O
survival	 O
,	 O
PFS	 B-METRIC
,	 O
and	 O
side	 O
effects	 O
.	 O

The	 O
results	 O
of	 O
this	 O
study	 O
revealed	 O
that	 O
there	 O
is	 O
no	 O
significant	 O
difference	 O
between	 O
the	 O
m	 O
-	 O
DCF	 O
and	 O
[P1]	 O
EOX	 O
regimens	 O
[P2]	 O
regarding	 O
survival	 O
,	 O
PFS	 B-METRIC
,	 O
and	 O
side	 O
effects	 O
.	 O

However	 O
,	 O
considering	 O
the	 O
need	 O
for	 O
hospitalization	 O
due	 O
to	 O
continuous	 O
infusion	 O
of	 O
[P1]	 O
5-fluorouracil	 O
[P2]	 O
and	 O
lack	 O
of	 O
admission	 O
in	 O
the	 O
EOX	 O
group	 O
,	 O
this	 O
regimen	 O
seems	 O
to	 O
be	 O
more	 O
acceptable	 O
in	 O
patients	 O
who	 O
are	 O
unwilling	 O
to	 O
be	 O
hospitalized	 O
.	 O

However	 O
,	 O
considering	 O
the	 O
need	 O
for	 O
hospitalization	 O
due	 O
to	 O
continuous	 O
infusion	 O
of	 O
5-fluorouracil	 O
and	 O
lack	 O
of	 O
admission	 O
in	 O
the	 O
[P1]	 O
EOX	 O
group	 O
[P2]	 O
,	 O
this	 O
regimen	 O
seems	 O
to	 O
be	 O
more	 O
acceptable	 O
in	 O
patients	 O
who	 O
are	 O
unwilling	 O
to	 O
be	 O
hospitalized	 O
.	 O